Patents by Inventor Steven P. Seitz

Steven P. Seitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER
    Publication number: 20180079712
    Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Application
    Filed: April 1, 2016
    Publication date: March 22, 2018
    Inventors: James Aaron Balog, Emily Charlotte Cherney, Jay A. Markwalder, Steven P. Seitz, Weifang Shan, David K. Williams, Audris Huang, Susheel Jethanand Nara, Saumya Roy, Soodamani Thangavel, Ramesh Kumar Sistla, Srinivas Cheruku, Srinivasan Thangathirupathy, Yadagiri Kanyaboina, Nagalakshmi Pulicharla
  • IDO inhibitors
    Patent number: 9895330
    Abstract: There are disclosed compounds of Formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-di-oxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: February 20, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jay A Markwalder, James Aaron Balog, Audris Huang, Steven P Seitz
  • Inhibitors of lysine methyl transferase
    Patent number: 9822103
    Abstract: There are disclosed compounds that are inhibitors of EZH2, pharmaceutical compositions containing said compounds and methods of treating hyperproliferative, inflammatory, infectious, and immunoregulatory disorders and diseases utilizing the compounds of the invention.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: November 21, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Steven P. Seitz, Jay A. Markwalder, Ashok Vinayak Purandare
  • IDO inhibitors
    Patent number: 9790169
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: October 17, 2017
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Emily Charlotte Cherney, Weiwei Guo, Audris Huang, Jay A. Markwalder, Steven P. Seitz, Weifang Shan, David K. Williams, Natesan Murugesan, Susheel Jethanand Nara, Saumya Roy, Soodamani Thangavel, Ramesh Kumar Sistla, Srinivas Cheruku, Srinivasan Thangathirupathy, Yadagiri Kanyaboina, Nagalakshmi Pulicharla
  • IDO inhibitors
    Patent number: 9765018
    Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: September 19, 2017
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Bristol-Myers Squibb Company
    Inventors: Jay A. Markwalder, Steven P. Seitz, James Aaron Balog, Audris Huang, Sunil Kumar Mandal, David K. Williams, Amy C. Hart, Jennifer Inghrim
  • IDO inhibitors
    Patent number: 9758492
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: September 12, 2017
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Syngene International Limited
    Inventors: Jay A. Markwalder, Steven P. Seitz, James Aaron Balog, Audris Huang, Sunil Kumar Mandal, Shefali Srivastava, David K. Williams, Libing Chen
  • Inhibitors of lysine methyl transferase
    Patent number: 9738630
    Abstract: There are disclosed compounds that are inhibitors of EZH2, pharmaceutical compositions containing said compounds and methods of treating hyperproliferative, inflammatory, infectious, and immunoregulatory disorders and diseases, utilizing the compounds of the invention.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: August 22, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kyoung S. Kim, Liping Zhang, Ashok Vinayak Purandare, Steven P. Seitz
  • IDO INHIBITORS
    Publication number: 20170231999
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Application
    Filed: May 2, 2017
    Publication date: August 17, 2017
    Inventors: James Aaron Balog, Emily Charlotte Cherney, Weiwei Guo, Audris Huang, Jay A. Markwalder, Steven P. Seitz, Weifang Shan, David K. Williams, Natesan Murugesan, Susheel Jethanand Nara, Saumya Roy, Soodamani Thangavel, Ramesh Kumar Sistla, Srinivas Cheruku, Srinivasan Thangathirupathy, Yadagiri Kanyaboina, Nagalakshmi Pulicharla
  • Inhibitors of indoleamine 2,3-dioxygenase (IDO)
    Patent number: 9675571
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: June 13, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Audris Huang, Bin Chen, Libing Chen, Steven P. Seitz, Amy C. Hart, Jay A. Markwalder
  • IMMUNOREGULATORY AGENTS
    Publication number: 20170143649
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Application
    Filed: February 1, 2017
    Publication date: May 25, 2017
    Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Jay A. Markwalder, Steven P. Seitz, Emily Charlotte Cherney, Liping Zhang, Weifang Shan, Weiwei Guo, Audris Huang
  • Immunoregulatory agents
    Patent number: 9598422
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: March 21, 2017
    Assignee: Flexus Biosciences, Inc.
    Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Jay A. Markwalder, Steven P. Seitz, Emily Charlotte Cherney, Liping Zhang, Weifang Shan, Weiwei Guo, Audris Huang
  • INHIBITORS OF LYSINE METHYL TRANSFERASE
    Publication number: 20160297805
    Abstract: There are disclosed compounds that are inhibitors of EZH2, pharmaceutical compositions containing said compounds and methods of treating hyperproliferative, inflammatory, infectious, and immunoregulatory disorders and diseases utilizing the compounds of the invention.
    Type: Application
    Filed: November 18, 2014
    Publication date: October 13, 2016
    Inventors: Steven P. Seitz, Jay A. Markwalder, Ashok Vinayak Purandare
  • INHIBITORS OF LYSINE METHYL TRANSFERASE
    Publication number: 20160297806
    Abstract: There are disclosed compounds that are inhibitors of EZH2, pharmaceutical compositions containing said compounds and methods of treating hyperproliferative, inflammatory, infectious, and immunoregulatory disorders and diseases, utilizing the compounds of the invention.
    Type: Application
    Filed: November 18, 2014
    Publication date: October 13, 2016
    Inventors: Kyoung S. Kim, Liping Zhang, Ashok Vinandare Purandara, Steven P. Seitz
  • IDO INHIBITORS
    Publication number: 20160289171
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Application
    Filed: April 1, 2016
    Publication date: October 6, 2016
    Inventors: James Aaron Balog, Emily Charlotte Cherney, Weiwei Guo, Audris Huang, Jay A. Markwalder, Steven P. Seitz, Weifang Shan, David K. Williams, Natesan Murugesan, Susheel Jethanand Nara, Saumya Roy, Soodamani Thangavel, Ramesh Kumar Sistla, Srinivas Cheruku, Srinivasan Thangathirupathy, Yadagiri Kanyaboina, Nagalakshmi Pulicharla
  • IDO INHIBITORS
    Publication number: 20160200674
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.
    Type: Application
    Filed: August 26, 2014
    Publication date: July 14, 2016
    Applicant: Bristol-Myers Squibb Company
    Inventors: Jay A. Markwalder, Steven P. Seitz, James Aaron Balog, Audris Huang, Sunil Kumar Mandal, Shefali Srivastava, David K. Williams, Libing Chen
  • IDO INHIBITORS
    Publication number: 20160143870
    Abstract: There are disclosed compounds of Formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-di-oxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.
    Type: Application
    Filed: July 10, 2014
    Publication date: May 26, 2016
    Inventors: Jay A Markwalder, James Aaron Balog, Audris Huang, Steven P Seitz
  • IDO INHIBITORS
    Publication number: 20160137595
    Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-di-oxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Application
    Filed: July 1, 2014
    Publication date: May 19, 2016
    Inventors: Jay A. Markwalder, Steven P. Seitz, James Aaron Balog, Audris Huang, Sunil Kumar Mandal, David K. William, Amy C. Hart, Jennifer Inghrim
  • IMMUNOREGULATORY AGENTS
    Publication number: 20160137653
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Application
    Filed: November 5, 2015
    Publication date: May 19, 2016
    Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Jay A. Markwalder, Steven P. Seitz, Emily Charlotte Cherney, Liping Zhang, Weifang Shan, Weiwei Guo, Audris Huang
  • INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO)
    Publication number: 20160022619
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 28, 2016
    Inventors: James Aaron Balog, Audris Huang, Bin Chen, Libing Chen, Steven P. Seitz, Amy C. Hart, Jay A. Markwalder
  • Substituted pyrrolotriazines as protein kinase inhibitors
    Patent number: 8791257
    Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) pyrrolotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: July 29, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jay A. Markwalder, Brian E. Fink, Ashvinikumar V. Gavai, Liqi He, Soong-Hoon Kim, Steven P. Seitz